• 作者：Georgia Romero-Culleré ; s^a ; ^{gromero@althaia.cat} ; Joan Conejero-Sugrañ ; es^b ; Miguel Á ; ngel Gonzá ; lez-Viejo^c ; Jose Bruno-Montoro^d ; Pilar Ló ; pez-Guillen^b ; Montse Abenoza-Guardiola^a
• 关键词：Lesió ; n medular ; Toxina botulí ; nica ; Esfí ; nter uretral externo
• 刊名：Medicina Cl铆nica
• 出版年：2011
• 期刊代码：pca254_00257753
• 类别：med
• 出版时间：24 September 2011
• 卷：137
• 期：8
• 页码：346-348
• 文件大小：143 K

Background

To assess the efficacy and safety of botulinum toxin for sphincter hypertonia in patients with spinal cord injury (SCI).

Patients and methods

Non-control clinical trial on men with neurogenic detrussor-sphincter dyssynergia (DSD) due to SCI. 100 IU of Botox庐 were injected through the transperineal way on external urethral sphincter under electromyography and transrectal ultrasound guidance. The following parameters were determined: post-void residual (PVR), maximum urethral pressure (MUP), miction volume (M) and miction percentage (MP). The incidence of erectile dysfunction was evaluated using the International Index of Erectile Function questionnaire (IIEF-5 items).

Results

19 men with an average age of 40 years (ED 22-56) were included. The average time of monitoring was 546 days (20 months). As an average, an infiltration was done every 6 months, with an average of 2.7 infiltrations per patient (1-7). PVR dropped by 59.3 ml, p = 0.03; miction raised to 52 ml, p = 0.018; MP was improved by 17.2%, p = 0.011. Changes on MUP were not significant. Erectile dysfunction was not worse than the initial one (IIEF-5: 11.4 to 13).

Conclusion

The infiltration of the toxin into the sphincter through the transperineal way seems to be an effective and safe therapeutic option.